Crystallographic Analysis Reveals that Anticancer Clinical Candidate L-778,123 Inhibits Protein Farnesyltransferase and Geranylgeranyltransferase-I by Different Binding Modes
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Many signal transduction proteins that control growth, differentiation, and transformation, including Ras GTPase family members, require the covalent attachment of a lipid group by protein farnesyltransferase (FTase) or protein geranylgeranyltransferase type-I (GGTase-I) for proper function and for the transforming activity of oncogenic mutants. FTase inhibitors are a new class of potential cancer therapeutics under evaluation in human clinical trials. Here, we present crystal structures of the clinical candidate L-778,123 complexed with mammalian FTase and complexed with the related GGTase-I enzyme. Although FTase and GGTase-I have very similar active sites, L-778,123 adopts different binding modes in the two enzymes; in FTase, L-778,123 is competitive with the protein substrate, whereas in GGTase-I, L-778,123 is competitive with the lipid substrate and inhibitor binding is synergized by tetrahedral anions. A comparison of these complexes reveals that small differences in protein structure can dramatically affect inhibitor binding and selectivity. These structures should facilitate the design of more specific inhibitors toward FTase or GGTase-I. Finally, the binding of a drug and anion together could be applicable for developing new classes of inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, some high potency inhibitors coordinate Zn2+ via uncharged nitrogens with electron lone pairs, such as those found in sulfonamides18 and imidazoles6 (see Figure 13), that seem to interact more strongly than negatively charged nitro groups.7”
From AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins (2014) · cites this paper as [6]
Citations
Cites
None of the references could be matched to a known paper.
Research works printed but not linked: 53
- Tamanoi F., 2001, The Enzymes, 322
- Haluska P., Eur. J. Cancer, 38, 1700
- Caponigro F., 2003, Expert Opin. Invest. Drugs 12, 943−954.
- Cortes J. E., 2002, ZARNESTRATM (R115777), in chronic myeloid leukemia and other other hematological malignancies, Blood 31, 31.
- Fu H. W., 1999, Recent Prog. Horm. Res. 54, 315−342.
- Barbacid M., 1987, Annu. Rev. Biochem. 56, 779−827.
- Kato K., 1992, Proc. Natl. Acad. Sci. U.S.A. 89
- Cox A. D., 2001, Drugs 61, 723−732.
- Long S. B., 1998, Biochemistry 37, 9612−9618.
- Long S. B., 2000, Structure 8, 209−222.
- Strickland C. L., 1998, Biochemistry 37, 16601−16611.
- Park H.-W., 1800, Science, 275, 1804
- Long S. B., 2002, Nature 419, 645−650.
- Taylor J. S., EMBO J., 22, 5974
- Long S. B., 2001, Proc. Natl. Acad. Sci. U.S.A. 98
- Bell I. M., J. Med. Chem., 45, 2409
- deSolms S. J., J. Med. Chem., 46, 2984
- Strickland C. L., J. Med. Chem., 42, 2135
- Reiss Y., 1990, Inhibition of purified
- Dinsmore C. J., 2003, Chem. 3, 1075−1093.
- Sebti S. M., 2000, Oncogene 19, 6584−6593.
- Dinsmore C. J., J. Am. Chem. Soc., 123, 2108
- Huber H. E., J. Biol. Chem., 276, 24465
- Zhang F. L., J. Biol. Chem., 269, 23470
- Otwinowski Z., 1997, Methods Enzymol. 276A, 307−326.
- Brünger A. T., 1998, Acta Crystallogr., Sect. D 54, 905−921.
- Jones T. A., 1993, The manual
- Word J. M., J. Mol. Biol., 285, 1733
- Guex N., 1997, Electrophoresis 18, 2714−2723.
- De Moliner E., Eur. J. Biochem., 270, 3181
- Vogt A., 1991, Oncogene, 13, 1999
- Stark W. W., Jr., Am. J. Physiol., 275, L63
- Sun J., 2003, Cancer Res. 63, 8922−8929.
- Walters C. E., J. Immunol., 168, 4094
- Lobell R. B., 2001, Cancer Res. 61, 8758−8768.
- Wong W. W., 2002, Leukemia 16, 508−519.
- Reid T. S., 2004, Biochemistry 43, 6877−6884.
- Del Villar K., J. Biol. Chem., 274, 27017
- Buckner F. S., 2002, Mol. Biochem. Parasitol. 122, 181−188.
- Murthi K. K., 1935, Bioorg. Med. Chem. Lett., 13, 1937
- Chakrabarti D., 1998, Mol. Biochem. Parasitol. 94, 175−184.
- Segel, I. H. (1975)Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady-State Systems, pp 465−504, Wiley, New York.
- Theorell H., 1965, Arch. Biochem. Biophys. 110, 413−421.
- Pylypenko O., 2003, Mol. Cell 11, 483−494.
- Zhang H., 2000, Structure 8, 241−251.
- Scholten J. D., J. Biol. Chem., 272, 18081
- Hajduk P. J., J. Med. Chem., 43, 4786
- Szczepankiewicz B. G., J. Am. Chem. Soc., 125, 4096
- Erlanson D. A., 2000, Proc. Natl. Acad. Sci. U.S.A. 97
- Seidel H. M., 1994, Biochemistry 33, 5641−5646.
- Zhou G., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
- Milner-White E. J., Biochem. J., 122, 740
- Abbreviations FPP, farnesyl diphosphate
Cited by
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,754
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2221 · Cited by 451
“The CAAX mimetic FTI L778123 has been shown to bear significant inhibitory activity against GGTase I (besides FTase”
BackgroundInhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382
AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins
Santos-Martins, D., Forli, S., Ramos, M. J., & Olson, A. J. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500209e · Cited by 318
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
Basso, A. D., Kirschmeier, P., & Bishop, W. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500012-jlr200 · Cited by 297
Lane, K. T., & Beese, L. S. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600002-jlr200 · Cited by 280
Self-citationTherapeutic intervention based on protein prenylation and associated modifications
Gelb, M. H., Brunsveld, L., Hrycyna, C. A., Michaelis, S., Tamanoi, F., Van Voorhis, W. C., & Waldmann, H. (2006) · Nature Chemical Biology · doi:10.1038/nchembio818 · Cited by 194
Zinc metalloproteins as medicinal targets
Anzellotti, A. I., & Farrell, N. P. (2008) · Chemical Society Reviews · doi:10.1039/b617121b · Cited by 172
Targeting Ras and Rho GTPases as opportunities for cancer therapeutics
Walker, K. M., & Olson, M. F. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.11.001 · Cited by 127
Hast, M. A., Nichols, C. B., Armstrong, S. M., Kelly, S. M., Hellinga, H. W., Alspaugh, J. A., & Beese, L. S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.250506 · Cited by 63
Self-citationStatins and Protein Prenylation in Cancer Cell Biology and Therapy
Garcia-Ruiz, C., Morales, A., & Fernandez-Checa, J. C. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800228715 · Cited by 61
Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization
Marchwicka, A., Kamińska, D., Monirialamdari, M., Błażewska, K. M., & Gendaszewska‐Darmach, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105424 · Cited by 61
“1 IC50 2 nM (FTase); IC50 98 nM (GGTase-I) (two completed clinical trials) 1S63 FTase: protein substrate; GGTase-I: protein and isoprenoid substrates competitive [58]”
BackgroundInfluentialShen, M., Pan, P., Li, Y., Li, D., Yu, H., & Hou, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.002 · Cited by 54
Chemical Biology of Lipidated Proteins
Triola, G., Waldmann, H., & Hedberg, C. (2012) · ACS Chemical Biology · doi:10.1021/cb200460u · Cited by 49
Unraveling the mechanism of the farnesyltransferase enzyme
Sousa, S. F., Fernandes, P. A., & Ramos, M. J. (2004) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-004-0612-6 · Cited by 48
Hast, M. A., Fletcher, S., Cummings, C. G., Pusateri, E. E., Blaskovich, M. A., Rivas, K. L., Gelb, M. H., A, W. C. V. V., Sebti, S. M., Hamilton, A. D., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.01.014 · Cited by 39
Self-citationComputational Macrocyclization: From de novo Macrocycle Generation to Binding Affinity Estimation
Wagner, V., Jantz, L., Briem, H., Sommer, K., Rarey, M., & Christ, C. D. (2017) · ChemMedChem · doi:10.1002/cmdc.201700478 · Cited by 34
Ashok, S., Hildebrandt, E. R., Ruiz, C. S., Hardgrove, D. S., Coreno, D. W., Schmidt, W. K., & Hougland, J. L. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00081 · Cited by 33
da Silva, C. H. T. D. P., da Silva, V. B., Resende, J., Rodrigues, P. F., Bononi, F. C., Benevenuto, C. G., & Taft, C. A. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.11.011 · Cited by 34
Hast, M. A., & Beese, L. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805330200 · Cited by 36
Self-citationKonstantinopoulos, P. A., & Papavassiliou, A. G. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.11.005 · Cited by 29
Mabanglo, M. F., Hast, M. A., Lubock, N. B., Hellinga, H. W., & Beese, L. S. (2013) · Protein Science · doi:10.1002/pro.2411 · Cited by 26
Self-citationPrenylation: From bacteria to eukaryotes
Marakasova, E. S., Ахматова, Н. К., Amaya, M., Eisenhaber, B., Eisenhaber, F., van Hoek, M. L., & Baranova, A. V. (2013) · Molecular Biology · doi:10.1134/s0026893313050130 · Cited by 23
Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation
Avendaño, C., & Menéndez, J. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-444-52824-7.00009-3 · Cited by 26
Wlodarczyk, N., Broc, D. L., Gilleron, P., Lemoine, A., Farce, A., Chavatte, P., Dubois, J., Pommery, N., Hénichart, J., Furman, C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101067y · Cited by 20
Liquid Chromatographic Analysis and Mass Spectrometric Identification of Farnesylated Peptides
Wotske, M., Wu, Y., & Wolters, D. A. (2012) · Analytical Chemistry · doi:10.1021/ac301437m · Cited by 18
Module Assembly for Designing Multivalent Mid‐Sized Inhibitors of Protein‐Protein Interactions
Ohkanda, J. (2013) · The Chemical Record · doi:10.1002/tcr.201300026 · Cited by 19
Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation
Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00010-7 · Cited by 17
Qiao, Y., Gao, J., Qiu, Y., Wu, L., Guo, F., Lo, K. K., & Li, D. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.007 · Cited by 13
Wang, Y., Xu, F., Nichols, C. B., Shi, Y., Hellinga, H. W., Alspaugh, J. A., Distefano, M. D., & Beese, L. S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00902 · Cited by 11
Self-citationMartewicz, S., Luni, C., Zhu, X., Cui, M., Hu, M., Qu, S., Buratto, D., Yang, G., Grespan, E., & Elvassore, N. (2020) · Cells · doi:10.3390/cells9112509 · Cited by 12
Machida, S., Usuba, K., Blaskovich, M. A., Yano, A., Harada, K., Sebti, S. M., Kato, N., & Ohkanda, J. (2008) · Chemistry - A European Journal · doi:10.1002/chem.200701634 · Cited by 11
Moorthy, N. S. H. N., Sousa, S. F., Ramos, M. J., & Fernandes, P. A. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2016.1144593 · Cited by 10
de Figueiredo, R. M., Coudray, L., & Dubois, J. (2007) · Organic & Biomolecular Chemistry · doi:10.1039/b709854e · Cited by 10
Small‐Molecule Modulation of Protein Lipidation: From Chemical Probes to Therapeutics
Wang, Z., Ying, J., Zhang, X., Chen, M., Xiao, Y., Zou, J., & Chen, B. (2023) · ChemBioChem · doi:10.1002/cbic.202300071 · Cited by 8
Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen
Bukhtiyarova, M., Cook, E. M., Hancock, P. J., Hruza, A. W., Shaw, A. W., Adam, G. C., Barnard, R. J. O., McKenna, P. M., Holloway, M. K., Bell, I. M., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00551 · Cited by 8
End, D. W., Mévellec, L., & Angibaud, P. R. (2006) · Topics in medicinal chemistry · doi:10.1007/7355_2006_003 · Cited by 7
Nguyen, U. T. T., Goodall, A., Alexandrov, K. A., & Abankwa, D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6382-6_1 · Cited by 6
Farnesyl Transferase Inhibitors
Bishop, W. R., Doll, R. J., & Kirschmeier, P. T. (2011) · The Enzymes · doi:10.1016/b978-0-12-381339-8.00015-9 · Cited by 11
Nair, P. P. S., Chandrashekarappa, K. K. H., Masagalli, J. N., Nagaraja, P. C., & Mahadevan, K. M. (2014) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 3
Structural Biochemistry of CaaX Protein Prenyltransferases
Hast, M. A., & Beese, L. S. (2011) · The Enzymes · doi:10.1016/b978-0-12-381339-8.00013-5 · Cited by 3
Self-citationReversible inactivation of the transcriptional function of P53 protein by farnesylation
Couderc, B., Penary, M., Tohfe, M., Pradines, A., Casteignau, A., Berg, D., & Favre, G. (2006) · BMC Biotechnology · doi:10.1186/1472-6750-6-26 · Cited by 4
“0.5 to 1 % of cellular proteins are isoprenylated (for review[10]), including members of the RasGTPase superfamily, several protein kinases and phosphatases, and a variety of proteins involved in nuclear integrity and centromere function [ 10-12 ].”
BackgroundInfluentialMechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I
Blanden, M. J., Ashok, S., & Hougland, J. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.14837-1 · Cited by 3
Kowluru, A., Gamage, S., Hali, M., & Gleason, N. F. (2022) · Cellular Physiology and Biochemistry · doi:10.33594/000000557 · Cited by 2
Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades
Klochkov, S. G., Неганова, М. Е., & Aleksandrova, Y. R. (2020) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162020050118 · Cited by 2
Moorthy, N. S. H. N., Sousa, S. F., Ramos, M. J., & Fernandes, P. A. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1578-y · Cited by 1
“…the reaction of more than 60 signal transduction proteins in the eukaryotic cell, including members of the Rho and Ras superfamily of G proteins because it catalyses the transfer of a 15-carbon isoprenoid lipid moiety to the C terminus of this protein (Casey and Seabra, 1996; Reid et al., 2004a).”
BackgroundAvendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00011-x · Cited by 1
CaaX‐Protein Prenyltransferase Inhibitors
Schlitzer, M., Ortmann, R., & Altenkämper, M. (2009) · doi:10.1002/9780470508169.ch34 · Cited by 1
Troutman, J. M. (2006) · UKnowledge (University of Kentucky)
A multipurpose probe for identification and mechanistic analysis of prenylation inhibitors
Yehia, R., Giladi, M., & Haitin, Y. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2700494
Thirty years of plant farnesylation research: Few substrates, many gaps, and a clear path forward
Daszkowska‐Golec, A., Sundaresan, A. P., & Distefano, M. D. (2026) · Journal of Plant Physiology · doi:10.1016/j.jplph.2026.154887
BindingDB (2022) · UC San Diego · doi:10.7270/q2bg2sps
BindingDB (2011) · UC San Diego · doi:10.7270/q2sn096q
Metadata
- Authors
- Reid, T. S., Long, S. B., & Beese, L. S.
- Affiliations
- Duke Medical Center (US)
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2004-06-23
- Volume
- 43
- Issue
- 28
- Pages
- 9000-9008
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2016552910
- Cited by
- 51
- References
- 1
- Citations by year
- 2026: 2 · 2023: 2 · 2022: 3 · 2020: 5 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 2
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM52382)
- National Center for Research Resources (RR07 707)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- farnesyltransferase, geranylgeranyltransferase I, Ras GTPase, lipid modification, competitive inhibition, tetrahedral anions, enzyme selectivity, crystal structure, anticancer drug design
- MeSH terms
- Animals, Antineoplastic Agents, Binding, Competitive, Enzyme Inhibitors, Humans, Imidazoles, Models, Molecular, Protein Binding, Protein Conformation, Structure-Activity Relationship, Crystallography, X-Ray, Alkyl and Aryl Transferases, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.